Filtered Listing Testing

Congratulations to former BrightFocus grantee Joel S. Schuman, MD, who has been appointed chair of ophthalmology at New York University's Langone Medical Center in New York City. Previously he was professor and chair of ophthalmology at the University of Pittsburgh Medical Center (UPMC) and director of the UPMC Eye Center

Read how Donald Zack, a past BrightFocus grantee, has been advancing cures for glaucoma and macular degeneration.

BrightFocus Foundation joins with Montgomery County, MD Executive Isiah Leggett to announce the County’s commitment to Dementia Friendly America, a rapidly growing, national initiative to create communities that better recognize and help those affected with dementia, their families and care partners.

Stacy Pagos Haller, BrightFocus Foundation's President and CEO, urges the Food and Drug Administration to strongly support expanded use of neurodiagnostic tools to assess cognitive function.

Download the fall edition of our macular degeneration research newsletter and read about new treatments that are on the horizon, the latest research grants awarded for pioneering macular degeneration research, the first-ever bionic eye for patients with macular degeneration, and more.

In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent age-related macular degeneration (AMD), the most common form of blindness among older Americans.

A research team, supported in part by BrightFocus Foundation, wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. After combing through massive amounts of medical chart data, their answer is yes.

Learn about a BrightFocus grantee's role in confirming amyloid's role in early Alzheimer's, a record-breaking $5.9 million in new Alzheimer's research awarded by BrightFocus Foundation, how to be prepared if you need to search for someone who has Alzheimer's disease, and more, in the winter edition of our Alzheimer's disease newsletter.

Explore the mystery of normal-tension glaucoma, a medication that may reduce the risk of open-angle glaucoma, learn about 15 new glaucoma research grants awarded by BrightFocus Foundation, and more in the fall edition of our glaucoma newsletter.